Expression Level of MiRNA in the Peripheral Blood of Patients with Multiple Myeloma and Its Clinical Significance

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2021 Jun 21

PMID 34150128

Citations 2

Authors

Guangbao Li

Jianwen Yin

Zutong Wu

Shizhong Li

Aijun He

Zhenzhen Sun

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the expression level of serum miRNA-192-5p and its clinical value in the diagnosis and care of patients with multiple myeloma (MM).

Methods: Eighty-eight patients with MM admitted to our hospital from June 2017 to April 2020 were selected as the observation group. In addition, 70 patients who received osteoporosis testing in our hospital in the corresponding period but were excluded from having MM and haematological malignancy were selected as the control group. The relative expression level of serum miRNA-192-5p was detected. The expression level of serum miRNA and its correlation with patient-related clinical parameters were compared and analyzed. The ROC curve was used to analyze its diagnostic efficacy for MM.

Results: The relative expression level of serum miRNA-192-5p in MM patients was remarkably lower than that in the control group (P < 0.05); the AUC area of serum miRNA-192-5p in patients with a diagnosis of MM was 0.853, with a cutoff value of 0.72, the sensitivity of 86.30%, and the specificity of 81.20%, P = 0.030. The relative expression level of miRNA-192-5p in the serum of patients with high β2-MG and creatinine levels was markedly reduced compared to that in patients with low β2-MG levels (P < 0.05); the relative expression level of miRNA-192-5p in the serum of patients with low hemoglobin and albumin levels was markedly reduced compared to that in patients with normal hemoglobin and albumin (P < 0.05); and there was significantly negative correlation between the relative expression level of miRNA-192-5p in the serum of MM patients and IgG and IgA levels, respectively (P < 0.05).

Conclusion: miRNA-192-5p may serve as an auxiliary diagnostic tool in the diagnosis of MM. Furthermore, because there is certain correlation between serum miRNA-192-5p and MM progression and prognosis, it may be regarded as a novel marker for MM monitoring.

Citing Articles

Molecular mechanisms of miR-192 in cancer: a biomarker and therapeutic target.

Yang Y, Razak S, Ismail I, Ma Y, Yunus M Cancer Cell Int. 2025; 25(1):94.

PMID: 40087755 DOI: 10.1186/s12935-025-03666-5.

Role of Non-Coding RNAs in Diagnosis, Prediction and Prognosis of Multiple Myeloma.

Dubaj M, Bigosinski K, Dembowska A, Mlak R, Szudy-Szczyrek A, Malecka-Massalska T Cancers (Basel). 2024; 16(5).

PMID: 38473390 PMC: 10931522. DOI: 10.3390/cancers16051033.

Effect of Autologous Stem Cell Transplantation Combined with Modified VTD Regimen on Elderly Patients with Multiple Myeloma and Its Influence on miRNA Cytokines.

Bai Z, Shen J Comput Math Methods Med. 2022; 2022:6320329.

PMID: 35222688 PMC: 8865993. DOI: 10.1155/2022/6320329.

References

Momen-Heravi F, Saha B, Kodys K, Catalano D, Satishchandran A, Szabo G . Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. J Transl Med. 2015; 13:261. PMC: 4533956. DOI: 10.1186/s12967-015-0623-9. View

Valcourt D, Day E . Dual Regulation of miR-34a and Notch Signaling in Triple-Negative Breast Cancer by Antibody/miRNA Nanocarriers. Mol Ther Nucleic Acids. 2020; 21:290-298. PMC: 7332498. DOI: 10.1016/j.omtn.2020.06.003. View

Ezponda T, Dupere-Richer D, Will C, Small E, Varghese N, Patel T . UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition. Cell Rep. 2017; 21(3):628-640. PMC: 5706555. DOI: 10.1016/j.celrep.2017.09.078. View

Hassan S, El-Khazragy N, Elshimy A, Aboelhussein M, Saleh S, Fadel S . In vitro knock-out of miR-155 suppresses leukemic and HCV virus loads in pediatric HCV-4-associated acute lymphoid leukemia: A promising target therapy. J Cell Biochem. 2019; 121(4):2811-2817. DOI: 10.1002/jcb.29512. View

Keller A, Fehlmann T, Backes C, Kern F, Gislefoss R, Langseth H . Competitive learning suggests circulating miRNA profiles for cancers decades prior to diagnosis. RNA Biol. 2020; 17(10):1416-1426. PMC: 7549715. DOI: 10.1080/15476286.2020.1771945. View

Deng S, Zhang X, Qin Y, Chen W, Fan H, Feng X . miRNA-192 and -215 activate Wnt/β-catenin signaling pathway in gastric cancer via APC. J Cell Physiol. 2020; 235(9):6218-6229. DOI: 10.1002/jcp.29550. View

Xu J, Pfarr N, Endris V, Mai E, Md Hanafiah N, Lehners N . Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation. Oncogenesis. 2017; 6(5):e337. PMC: 5523069. DOI: 10.1038/oncsis.2017.36. View

Musto P, Statuto T, Valvano L, Grieco V, Nozza F, Vona G . An update on biology, diagnosis and treatment of primary plasma cell leukemia. Expert Rev Hematol. 2019; 12(4):245-253. DOI: 10.1080/17474086.2019.1598258. View

Pourhanifeh M, Mahjoubin-Tehran M, Shafiee A, Hajighadimi S, Moradizarmehri S, Mirzaei H . MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis. IUBMB Life. 2019; 72(3):314-333. DOI: 10.1002/iub.2211. View

10.

Chen W . [The guidelines for the diagnosis and management of multiple myeloma in China (2017 revision): interpretation of treatment of relapsed/refractory multiple myeloma]. Zhonghua Nei Ke Za Zhi. 2017; 56(11):799-800. DOI: 10.3760/cma.j.issn.0578-1426.2017.11.004. View

11.

Ramakrishnan V, DSouza A . Signaling Pathways and Emerging Therapies in Multiple Myeloma. Curr Hematol Malig Rep. 2016; 11(2):156-64. DOI: 10.1007/s11899-016-0315-4. View

12.

Ge Y, Yan X, Jin Y, Yang X, Yu X, Zhou L . MiRNA-192 [corrected] and miRNA-204 Directly Suppress lncRNA HOTTIP and Interrupt GLS1-Mediated Glutaminolysis in Hepatocellular Carcinoma. PLoS Genet. 2015; 11(12):e1005726. PMC: 4692503. DOI: 10.1371/journal.pgen.1005726. View

13.

Liu Z, Zhang G, Yu W, Gao N, Peng J . miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1. Biochem Biophys Res Commun. 2015; 469(3):692-7. DOI: 10.1016/j.bbrc.2015.11.136. View

14.

Gao F, Yang T, Liu X, Xiong F, Luo J, Yi Y . MiRNA Targeted NP Genome of Live Attenuated Influenza Vaccines Provide Cross-Protection against a Lethal Influenza Virus Infection. Vaccines (Basel). 2020; 8(1). PMC: 7158662. DOI: 10.3390/vaccines8010065. View

15.

Berenson J, Crowley J, Grogan T, Zangmeister J, Briggs A, Mills G . Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002; 99(9):3163-8. DOI: 10.1182/blood.v99.9.3163. View

16.

Peller P . Multiple myeloma. PET Clin. 2015; 10(2):227-41. DOI: 10.1016/j.cpet.2014.12.008. View

17.

Yang Y, Lin J, Ma Z, Li J, Li D, Wang B . Potential roles of microRNAs and their target genes in human multiple myeloma. Eur J Haematol. 2017; 99(2):178-185. DOI: 10.1111/ejh.12901. View

18.

Yang K, Wang S, Cheng Y, Tian Y, Hou J . Role of miRNA-21 in the diagnosis and prediction of treatment efficacy of primary central nervous system lymphoma. Oncol Lett. 2019; 17(3):3475-3481. PMC: 6396200. DOI: 10.3892/ol.2019.9941. View

19.

Morawska M, Grzasko N, Kostyra M, Wojciechowicz J, Hus M . Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol. 2014; 33(4):113-9. DOI: 10.1002/hon.2149. View

20.

Hassan M, Morise F, Osman N, Salam L, Yehia H, Hamdi M . Micro RNA-192 Is Negatively Associated With Cardiovascular Events Among Wait-Listed Potential Kidney Transplant Recipients on Hemodialysis Over a 5-year Follow-up Period. Transplant Proc. 2019; 51(7):2237-2240. DOI: 10.1016/j.transproceed.2019.02.044. View